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Abstract
B cell-activating factor (BAFF) has a key role in promoting B-
lymphocyte activation and survival in primary Sjögren's
syndrome (pSS). The cellular origin of BAFF overexpression in
salivary glands of patients with pSS is not fully known. We
investigated whether salivary gland epithelial cells (SGECs), the
main targets of autoimmunity in pSS, could produce and
express BAFF. We used quantitative RT-PCR, ELISA and
immunocytochemistry in cultured SGECs from eight patients
with pSS and eight controls on treatment with IL-10, tumor
necrosis factor α (TNF-α), IFN-α and IFN-γ. At baseline, BAFF
expression in SGECs was low in pSS patients and in controls.
Treatment with IFN-α, IFN-γ and TNF-α + IFN-γ increased the
level of BAFF mRNA in pSS patients (the mean increases were
27-fold, 25-fold and 62-fold, respectively) and in controls (mean
increases 19.1-fold, 26.7-fold and 17.7-fold, respectively), with
no significant difference between patients and controls.
However, in comparison with that at baseline, stimulation with
IFN-α significantly increased the level of BAFF mRNA in SGECs
of pSS patients (p = 0.03) but not in controls (p = 0.2), which
suggests that SGECs of patients with pSS are particularly
susceptible to expressing BAFF under IFN-α stimulation.
Secretion of BAFF protein, undetectable at baseline, was
significantly increased after IFN-α and IFN-γ stimulation both in
pSS patients (40.8 ± 12.5 (± SEM) and 47.4 ± 18.7 pg/ml,
respectively) and controls (24.9 ± 8.0 and 9.0 ± 3.9 pg/ml,
respectively), with no significant difference between pSS and
controls. Immunocytochemistry confirmed the induction of
cytoplasmic BAFF expression after stimulation with IFN-α and
IFN-γ. This study confirms the importance of resident cells of
target organs in inducing or perpetuating autoimmunity.
Demonstrating the capacity of SGECs to express and secrete
BAFF after IFN stimulation adds further information to the pivotal
role of these epithelial cells in the pathogenesis of pSS, possibly
after stimulation by innate immunity. Our results suggest that an
anti-BAFF therapeutic approach could be particularly interesting
in pSS.
Introduction
Primary Sjögren's syndrome (pSS) is a prototypical autoim-
mune disorder characterized by lymphocytic infiltration of sali-
vary and lachrymal glands leading to xerostomia and
keratoconjunctivitis sicca. Polyclonal B cell activation and sys-
temic production of autoantibodies are the main laboratory
findings characterizing pSS [1]. Patients with pSS are at
increased risk for the development of B cell non-Hodgkin's
lymphoma, and some evidence exists that such lymphomas
[2,3] arise from autoreactive B cells [4-6].
BAFF = B cell-activating factor; DMEM = Dulbecco's modified Eagle's medium; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf 
serum; IFN = interferon; IL = interleukin; MPO = myeloperoxidase; PBS = phosphate-buffered saline; pSS = primary Sjögren's syndrome; RA = rheu-
matoid arthritis; RT-PCR = reverse transcriptase polymerase chain reaction; SGECs = salivary gland epithelial cells; SLE = systemic lupus erythema-
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Recruitment of activated and memory B cells in salivary gland
infiltrates [7], germinal center formation in 20 to 25% of
patients, and local secretion of autoantibodies [8] demon-
strate the pathogenic role in situ of B cell activation in pSS.
Increased expression of a newly described cytokine, termed B
cell-activating factor (BAFF) or B-lymphocyte stimulator
(BLyS) [9-12], might explain this pathogenic B cell activation
in several systemic autoimmune diseases including pSS.
BAFF has a crucial role in B cell maturation [13-15], plasma
cell survival [15], antibody response promotion [16] and immu-
noglobulin-class switch recombination [17]. Interestingly, for
reasons that are not fully understood, autoreactive B cells
depend on BAFF for survival more than alloreactive B cells do
[18,19]. The involvement of BAFF in the pathogenesis of
autoimmune diseases is well illustrated by BAFF overexpres-
sion in mice models, which leads to autoimmune disease mim-
icking rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE) and pSS, as well as a twofold increase in occurrence of
B cell lymphoma [13]. In humans, an increased serum level of
BAFF was reported in patients with RA [20,21] and SLE
[22,23], but the more consistent findings concerned pSS,
with an increase in BAFF level reported in all four published
surveys of patients with pSS [24-27]. Moreover, we demon-
strated in pSS a correlation between the serum level of BAFF
and serum level of immunoglobulins and titers of autoantibod-
ies [25,28].
Using immunohistochemistry, we and others have shown
increased expression of BAFF in salivary glands of patients
with pSS [24,29,30]. We recently extended these results by
demonstrating a threefold increase in BAFF mRNA level in the
two main target organs of pSS salivary glands and the ocular
surface [31]. However, the cellular origin of BAFF expression
in salivary glands of patients with pSS is not well understood.
Indeed, monocytes and myeloid dendritic cells, the main cell
types involved in the physiological expression of BAFF [32],
are not present in large amounts in salivary glands of patients
with pSS. Using immunohistochemistry, we localized BAFF
expression in the T cell infiltrate and ductal epithelial cells [29].
However, we could not eliminate the possibility that this find-
ing was due to the passive fixation of BAFF on its receptor.
Glandular epithelial cells are the main target cells of autoimmu-
nity in pSS [33], currently considered to be an autoimmune
epithelitis [34]. These cells, after exogenous aggression, pos-
sibly of viral origin [35], express co-stimulation molecules [36-
38] and lymphoid chemokines [39] and are suitably equipped
to present autoantigens, which suggests that salivary gland
epithelial cells (SGECs) can act as non-professional antigen-
presenting cells [40]. Thus, we proposed that SGECs could
also express BAFF in pSS. To avoid the limitation of immuno-
histochemical studies, potentially showing passive BAFF fixa-
tion on one of its receptors rather than the cellular production
of BAFF, we investigated BAFF mRNA expression in salivary
gland cell lines. We then investigated BAFF mRNA expression
in SGECs from patients with pSS and controls, and BAFF pro-
tein secretion in supernatants from these cell cultures. We
evaluated the contribution of different patterns of cytokine
environment on BAFF mRNA and protein expression, using
stimulations with various cytokines known to have a patho-
genic role in pSS. Our results demonstrate the inducible
expression of BAFF mRNA and BAFF protein under stimula-
tion by IFN in SGECs, which might have a key pathogenic role
in pSS autoimmune epithelitis.
Materials and methods
Patients
Eight female patients with pSS (mean age 43 years; range 35
to 59 years) referred to the Department of Rheumatology,
Bicêtre Hospital, France, were enrolled in the study. pSS was
defined in accordance with the American/European consen-
sus group (AECG) criteria [41]. Seven of eight patients had
serum anti-SSA antibodies, and four also had anti-SSB anti-
bodies. All except one had a positive lip biopsy (Chisholm
score of 3 or 4). The only patient with a negative lip biopsy also
had anti-SSA antibodies and fulfilled AECG criteria. No
patients had evidence of other connective tissue disease.
Biopsy specimens of minor salivary glands were obtained from
eight control subjects (seven women and one man, mean age
54 years; range 35 to 79 years) with sicca symptoms without
autoantibodies or lymphoid infiltrates on lip biopsy. The study
received approval from the local ethics committee, and
informed consent was obtained from all study subjects.
Reagents
DMEM, Ham's F-12 and DMEM/F-12 were from Invitrogen
(Cergy Pontoise, France). FCS and 0.125% trypsin-EDTA
were from Seromed (Berlin, Germany). Hydrocortisone was
from Pharmacia (Guyancourt, France). Insulin was from Novo
Nordisk A/S (Denmark). Epidermal growth factor was from BD
Bioscience (Le Pont de Claix, France). Recombinant human
IFN-γ (IFN-γ), IFN-α and IL-10 were purchased from R&D Sys-
tems (Lilles, France). Recombinant human tumor necrosis fac-
tor-α (TNF-α) and cytokeratin 19 were from Sigma-Aldrich
(Saint Quentin Fallavier, France). Cytokeratin 7 was from Bio-
genex (Antony, France). Cytokeratins 20 and 903, and CD45
and EnVision Detection Kit peroxidase/diaminobenzidine, rab-
bit/mouse were from DakoCytomation (Trappes, France).
Myeloperoxidase (MPO) was from Novocastra (Newcastle,
UK). Rat anti-human BAFF (Buffy-2) was kindly provided by
Pascal Schneider (Apotech).
Cell lines
HSG is a cell line derived from neoplastic epithelial duct cells
of the human salivary gland (a gift of Bruce Baum and Marc
Kok (U.S. National Institutes of Health)), grown in DMEM/F-12
supplemented with 10% FCS, penicillin (100 IU/ml) and strep-
tomycin (100 µg/ml). Human erythroleukemia K562 cells sta-
bly expressing BAFF were grown in RPMI mediumAvailable online http://arthritis-research.com/content/8/2/R51
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supplemented with 10% FCS, penicillin (100 IU/ml) and strep-
tomycin (100 µg/ml). All cell lines were incubated at 37°C
under 5% CO2.
Cultures of SGECs and treatment
Primary cultures of SGECs were established from minor sali-
vary glands as described [42]. In brief, each lobule was cut
into small fragments and set in six 75 cm2 flasks with basal epi-
thelial medium (a 3:1 mixture of Ham's F-12 and DMEM) sup-
plemented with 2.5% FCS, epidermal growth factor (10 ng/
ml), hydrocortisone (0.4 µg/ml), insulin (0.5 µg/ml), penicillin
(100 IU/ml) and streptomycin (100 µg/ml) and incubated at
37°C under 5% CO2. After 4 to 5 weeks of culture, at 70 to
80% confluence, cells were stimulated with IL-10 (100 ng/ml),
IFN-α (2,400 U/ml), IFN-γ (5 ng/ml), TNF-α (1 ng/ml) or IFN-γ
(5 ng/ml) + TNF-α (1 ng/ml) for 2 days for real-time quantita-
tive RT-PCR and ELISA. Cells were then dissociated with
0.125% trypsin-EDTA solution.
Real-time quantitative RT-PCR
Total RNA was isolated from epithelial cells with use of the
RNeasy Mini kit from Qiagen (Courtaboeuf, France). cDNA
synthesis involved the use of Enhanced Avian HS RT-PCR Kit
from Sigma-Aldrich (Saint Quentin Fallavier, France). BAFF
and β-actin cDNA levels were determined by use of Light
Cycler-based kinetic quantitative PCR (Roche Diagnostics,
Meylan, France). BAFF and β-actin PCR products were
detected by the use of LightCycler FastStart DNA Master
SYBR Green I (Roche Diagnostics). To correct for variations
in mRNA recovery and reverse transcription yield, the amount
of BAFF cDNA was normalized with β-actin. Results were
expressed as an increase in normalized values over that
observed with untreated cells. Amplification primers for the
human genes were as follows: BAFF, 5'-TGAAACACCAAC-
TATACAAAAAG-3' and 5'-TCAATTCATCCCCAAAGACAT-
3'; β-actin, 5'-GCTGTGCTACGTCGCCCT-3' and 5'-AAGG-
TAGTTTCGTGGATGCC-3'. Primers were designed to be
specific to full-length BAFF, excluding any amplification of
delta-BAFF, an alternative splice variant lacking exon 3. Quan-
titative PCR runs were considered only if amplification efficien-
cies were high (slopes ranging from -3.2 to -3.8). Each sample
was processed in duplicate, with initial incubation at 96°C for
10 minutes, and thermal conditions followed 40 cycles of
95°C for 10 seconds, 60°C for 15 seconds, and 72°C for 20
seconds. For each run, serially diluted cDNA from K562 cells
was used for quantitative standards. We determined the cell
equivalence number of BAFF and β-actin mRNA in each sam-
ple in accordance with the standard curve generated from val-
ues obtained with K562. The unit number showing relative
BAFF mRNA level in each sample was determined as a value
of BAFF cell equivalence normalized with β-actin cell equiva-
lence. Melting-curve analysis was performed to assess the
specificity of PCR product.
Immunocytochemistry
SGECs were pelleted and fixed in AFA (alcohol, acetic acid
and formaldehyde) solution and embedded in paraffin wax.
Cell sections were dewaxed in 100% xylene and rehydrated
by serial incubations in ethanol, then water and PBS. Cell sec-
tions were pretreated by microwave heating in citrate buffer,
pH 7.3, for 15 minutes. After incubation for 10 minutes at room
temperature with bovine serum albumin in PBS, slides were
incubated for 30 minutes in a humid chamber at 4°C with 20
µg/ml mouse anti-human cytokeratin 7, cytokeratin 19, cytok-
eratin 20, cytokeratin 903, CD45, CD20, CD3, smooth mus-
cle actin and MPO. For BAFF stainings, slides were incubated
overnight with 20 µg/ml rat anti-human BAFF (Buffy-2). Spec-
imens were treated with 3% H2O2 in PBS for 5 minutes to
inactivate endogenous peroxidase activity. Then slides were
incubated at room temperature for 30 minutes each, with the
use of an EnVision Detection Kit peroxidase/diaminobenzi-
dine, rabbit/mouse. Staining involved the use of the 3-amino-
9-ethylcarbazole (AEC) chromogen (DakoCytomation). The
positive control for BAFF staining was a tonsil section. The
negative control consisted of staining SGECs with rat immu-
noglobulins by using the EnVision Detection Kit.
Figure 1
BAFF mRNA in the HSG cell line after stimulation by cytokines BAFF mRNA in the HSG cell line after stimulation by cytokines. (a) RT-
PCR results showing expression of B cell-activating factor (BAFF) 
mRNA by the HSG cell line after 48 hours of stimulation with IL-10 
(100 ng/ml), IFN-α (2,400 U/ml), IFN-γ (5 ng/ml), tumor necrosis factor 
(TNF)-α (1 ng/ml) and IFN-γ (5 ng/ml) + TNF-α (1 ng/ml). (b) Time 
course of induction of BAFF mRNA in the HSG cell line 9, 24, 48 and 
72 hours after stimulation with IFN-γ (5 ng/ml). Error bars indicate SEM.Arthritis Research & Therapy    Vol 8 No 2    Ittah et al.
Page 4 of 9
(page number not for citation purposes)
Detection and quantification of BAFF secretion
BAFF levels in the supernatants of primary cultures of unstim-
ulated or stimulated SGECs were determined by using an
ELISA kit from R&D Systems.
Data analysis and statistics
Results are shown as means ± SEM. Statistical comparison
involved the Mann-Whitney U test and the Wilcoxon matched-
pairs test with use of Analyse-it software (Analyse-it Software
Ltd, Leeds, UK) for Microsoft Excel.
Results
BAFF expression in salivary gland cell lines
Quantitative RT-PCR detected low BAFF gene expression at
baseline in the HSG cell line. A significant increase was
observed after stimulation with IFN-γ and IFN-γ + TNF-α for 48
Figure 2
Immunocytochemical analysis of salivary epithelial cells Immunocytochemical analysis of salivary epithelial cells. Cells were obtained from minor salivary glands (a–e) and the HSG cell line (f–i). Positive 
staining for cytokeratin 7 (a) and cytokeratin 19 (b) and the absence of staining with cytokeratin 20 (c) indicates the specificity of ductal epithelial 
cell origin. The absence of staining for myeloperoxidase (MPO) (d), CD45 (e), CD20 (f), CD3 (g) and smooth muscle actin (h) before (subpanels 1 
in (d–h)) and after (subpanels 2 in (d–h)) stimulation with IFN-α excludes the possibility of contamination with myeloid cell. Positive staining with 
cytokeratin 7 (i) and the absence of staining with cytokeratin 20 (j) indicate the ductal epithelial origin of HSG cell lines. Negative staining with mye-
loperoxydase (MPO) (k) and CD45 (l) excludes the possibility of contamination with myeloid cells.Available online http://arthritis-research.com/content/8/2/R51
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hours (the mean increases were 3.4-fold and 3.6-fold, respec-
tively). No significant change was observed with IL-10, IFN-α
or TNF-α (Figure 1a). Next we investigated the time course of
BAFF mRNA induction. The level of BAFF mRNA peaked 48
hours after the addition of IFN-γ (Figure 1b). Subsequently,
these positive results in epithelial cell lines led us to determine
whether they could be extended to primary epithelial cells in
patients with pSS and controls.
Epithelial origin of salivary gland cells
To exclude cell dedifferentiation during primary culture and
after cytokine stimulation, morphological characteristics and
cytokeratin 7 staining for ductal SGECs [43] were evaluated
in cells from patients with pSS and from controls. All tested
samples were 95 to 100% positive for cytokeratin 7, cytoker-
atin 19 and cytokeratin 903 but not for cytokeratin 20, which
confirmed the ductal epithelial origin of these cells (Figure 2a–
c). Moreover, complementary staining with MPO, CD20, CD3,
CD45 and smooth muscle actin excluded the possibility of
contamination with myeloid cells, B cells, T cells or myoepithe-
lial cells (Figure 2d–h). The HSG cell line had exactly the same
staining pattern as epithelial cells from patients (positive for
cytokeratin 7 and negative for cytokeratin 20, MPO and
CD45; Figure 2i–l).
Expression of BAFF mRNA in ductal SGECs
At baseline, BAFF expression in SGECs was low in patients
with pSS and not significantly different from that of controls
(Figure 3 and Table 1). Treatment with IFN-α, IFN-γ and TNF-
α + IFN-γ increased the level of BAFF mRNA in patients with
pSS (mean increases 27-fold, 25-fold and 62-fold, respec-
tively) and in controls (mean increases 19.1-fold, 26.7-fold and
17.7-fold, respectively), with no significant difference between
patients and controls (p = 0.5, 0.8 and 0.07, respectively).
However, compared with that at baseline, the level of BAFF
mRNA was significantly increased with IFN-α in SGECs of
pSS patients (p = 0.03) but not in those of controls (p = 0.2),
which suggests that SGECs of patients with pSS are particu-
larly susceptible to expressing BAFF under stimulation with
IFN-α. IFN-γ significantly induced BAFF expression in patients
with pSS and in controls (p = 0.008 and 0.03, respectively).
The effect on BAFF expression of stimulation of pSS-patient
cells with IFN-γ + TNF-α was not significantly different from
that of stimulation with IFN-γ alone (p = 0.15; Figure 3). No
change in BAFF expression was observed in cells stimulated
by IL-10 or TNF-α.
Expression of BAFF protein in ductal SGECs
Immunocytochemistry analysis in pSS-patient SGEC cell cul-
tures showed a slight positive staining at baseline (Figure 4b)
that was markedly enhanced after 48 hours with IFN-α (Figure
4c) and IFN-γ (Figure 4d).
Figure 3
Induction of BAFF mRNA by epithelial cells from minor salivary glands Induction of BAFF mRNA by epithelial cells from minor salivary glands. 
Results are from seven patients with pSS and from seven controls, 48 
hours after stimulation with IL-10 (100 ng/ml), IFN-α (2,400 U/ml), IFN-
γ (5 ng/ml), tumor necrosis factor (TNF)-α (1 ng/ml) and IFN-γ (5 ng/ml) 
+ TNF-α (1 ng/ml). All samples were processed in duplicate. Error bars 
indicate SEM. BAFF, B cell-activating factor.
Table 1
Modulation of BAFF mRNA expression with stimulation by cytokines in seven patients with pSS and seven controls
Condition Patients with pSS (n = 7) Controls (n = 7)
BAFF mRNA/β-
actin mRNA
Fold increase over 
baseline
p versus baselinea BAFF mRNA/β-
actin mRNA
Fold increase over 
baseline
p versus baselinea
Baseline 0.44 ± 0.08 0.58 ± 0.2
IL-10 0.9 ± 0.36 3.38 0.3 0.7 ± 0.28 1.57 0.3
TNF-α 0.7 ± 0.28 1.62 0.27 1.0 ± 0.3 3.15 0.25
IFN-α 9.2 ± 2.47 26.96 0.03 13.7 ± 9.1 19.06 0.2
IFN-γ 10.4 ± 1.65 25.01 0.008 12.2 ± 4.37 26.65 0.03
IFN-γ + TNF-α 23.7 ± 6.86 62.06 0.008 8.3 ± 3.18 17.66 0.06
aPaired t test; bold values indicate significant difference (p < 0.05).
Ratios of BAFF mRNA to β-actin mRNA are expressed as means ± SEM. BAFF = B cell-activating factor; TNF = tumor necrosis factor.Arthritis Research & Therapy    Vol 8 No 2    Ittah et al.
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BAFF production by supernatant of primary epithelial 
cell culture
Because BAFF can be produced as a soluble protein, we
investigated whether soluble forms of BAFF could be secreted
by epithelial cells. At baseline and after stimulation with IL-10
and with TNF-α, ELISA detected no soluble BAFF in cells from
patients with pSS and from controls (Figure 5). Soluble BAFF
was detected by ELISA after stimulation with IFN-α in all
tested samples and after stimulation with IFN-γ in all samples
except three controls. Secretion of BAFF protein was signifi-
cantly increased after stimulation with IFN-α and IFN-γ both in
patients with pSS (40.8 ± 12.5 pg/ml, p = 0.03, and 47.4 ±
18.7 pg/ml, p = 0.02, respectively) and in controls (24.9 ± 8.0
pg/ml, p = 0.04, and 9.0 ± 3.9 pg/ml, p = 0.04, respectively).
After stimulation with IFN-α and IFN-γ, pSS patients and con-
trols showed no difference in BAFF protein secretion (p =
0.90 and p = 0.22, respectively). After stimulation with IFN-γ +
TNF-α, BAFF secretion showed a trend to a greater increase
in patients with pSS than in controls (p = 0.09; Figure 5).
Patients with PSS showed a trend toward potentiation of the
effect of IFN-γ when combined with TNF-α: the BAFF level
with IFN-γ + TNF-α was 79.3 ± 28.3 pg/ml, compared with
47.4 ± 18.7 pg/ml with IFN-γ alone (p = 0.08; Figure 5).
Discussion
Analysis of target organs of autoimmunity might help provide
insights into the pathogenesis of these diseases. We demon-
strate for the first time that BAFF, a critical molecule involved
in B cell survival, can be induced in SGECs under stimulation
with IFN at the mRNA and protein levels. Contamination by
myeloid cells, which could have been responsible for BAFF
secretion, was eliminated both in epithelial-cell cultures from
patients and in the HSG cell line, as seen by the total absence
of staining with myeloid markers in immunocytochemistry and
the 100% positivity with epithelial markers. Patterns of BAFF
mRNA expression as assessed by quantitative RT-PCR, and
BAFF secretion as assessed by ELISA after stimulation with
IFN-α, IFN-γ, and IFN-γ + TNF-α, were similar. Immunocyto-
chemistry confirmed the induction of BAFF after stimulation
with IFN-α or IFN-γ. Thus, we demonstrated a significant
increase in secreted BAFF protein. The functional effect of
BAFF on B cell survival was demonstrated previously [44].
Figure 4
Immunocytochemical analysis of BAFF expression in salivary epithelilal  cells from minor salivary glands Immunocytochemical analysis of BAFF expression in salivary epithelilal 
cells from minor salivary glands. Positive staining for B cell-activating 
factor (BAFF) 48 hours after stimulation with IFN-α (2,400 U/ml) (c) 
and with IFN-γ (5 ng/ml) (d) was markedly enhanced compared with 
baseline (b). (a) Negative control with polyclonal rat immunoglobulin.
Figure 5
ELISA results of BAFF secretion by salivary epithelial cells from minor  salivary glands ELISA results of BAFF secretion by salivary epithelial cells from minor 
salivary glands. Results are from eight patients with pSS and from eight 
controls. Supernatant of culture was harvested 48 hours after stimula-
tion with IL-10 (100 ng/ml), IFN-α (2,400 U/ml), IFN-γ (5 ng/ml), tumor 
necrosis factor (TNF)-α (1 ng/ml) and IFN-γ (5 ng/ml) + TNF-α (1 ng/
ml). Error bars indicate SEM. All samples were processed in duplicate. 
BAFF, B cell-activating factor.Available online http://arthritis-research.com/content/8/2/R51
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The present results confirm the recent demonstration in RA
[45] and multiple sclerosis [46] that resident cells of target
organs of autoimmunity could be induced to express BAFF
under environmental conditions. Our results also emphasize
that BAFF induction by cytokines is cell and disease depend-
ent. IL-10, a cytokine involved in BAFF stimulation in mono-
cytes and myeloid dendritic cells [47], did not influence BAFF
expression in SGECs, and neither did TNF-α, which was
recently reported to induce BAFF expression in fibroblast-like
synoviocytes of patients with RA [45]. Our results agree with
findings of the absence of a major role of TNF-α in the patho-
genesis of pSS, as illustrated by the lack of efficacy of TNF-α
blockers in this disease [48]. However, we observed a non-
significant trend suggesting a synergistic effect of IFN-γ and
TNF-α on the expression of both BAFF mRNA and protein. A
similar result was reported in synoviocytes from patients with
RA [45] and in astrocytes from patients with multiple sclerosis
[46]. This possible synergistic effect could be due to an induc-
tion of IFN-γ receptors by stimulation with TNF-α [49].
Interestingly, IFN-α and IFN-γ increased BAFF mRNA and pro-
tein levels in epithelial cells both from patients with pSS and
from controls but to a higher level in cells from patients.
Indeed, the increased BAFF mRNA level from baseline on
stimulation with both IFNs and IFN-γ + TNF-α reached statis-
tical significance in patients, whereas only IFN-γ stimulation
significantly increased the BAFF mRNA level in controls (Fig-
ure 3 and Table 1). Stimulation with both IFNs and with IFN-γ
+ TNF-α significantly increased BAFF protein level in the
supernatants of epithelial cells in pSS patients and controls,
as revealed by ELISA (Figure 5).
The possibly higher sensitivity to IFN stimulation, as revealed
by quantitative PCR, might be an intrinsic property of epithelial
cells in pSS and could be related to genetic factors. The
action of IFN-α on BAFF expression was previously studied
only on follicular dendritic cells of the germinal center [17].
IFN-α has a pivotal pathogenic role in SLE [50] and could also
be involved in the pathogenesis of pSS. Recently, a study
described IFN-α-positive cells in salivary gland infiltrates of
patients with pSS [51]. In addition, an IFN signature was dem-
onstrated in two microarray studies of salivary glands of
patients with pSS [31,52]. Moreover, Bave and colleagues
showed that the combination of anti-SSA antibodies and
apoptotic cells have a key role in the induction of IFN-α by
peripheral blood mononuclear cells in pSS [51]. Thus, in the
salivary glands of patients with pSS, the combination of apop-
totic bodies from epithelial cells and anti-SSA antibodies
could induce IFN-α production by infiltrating cells, which could
then induce BAFF expression by epithelial cells. Of course,
another source of IFN-α could be local viral infection, which
has frequently been suspected to induce pSS but never with
a definitive demonstration [53-56]. Whatever the cause of a
possible increase in IFN in the target organs of pSS, our
results suggest that SGECs of patients with pSS are particu-
larly susceptible to BAFF induction by IFN. Interestingly, BAFF
can be also increased in the ocular surface, another epithelial
target of autoimmunity in pSS: indeed, we found in conjuncti-
val smears a threefold increase in BAFF mRNA level in
patients with pSS in comparison with controls [31].
Our results add to the understanding of the pathogenic
involvement of SGECs in pSS. Such cells can not only
express and present autoantigens but can also concomitantly
activate B cells by the local secretion of BAFF. BAFF overex-
pression might have a pathogenic role in lymphomas, because
increased BAFF expression was observed in some lympho-
mas, and an increased BAFF level in serum was associated
with a worse prognosis in patients with lymphomas [57]. Thus,
local secretion of BAFF by epithelial cells might also explain
why lymphomas originate from the clonal transformation of sal-
ivary gland autoreactive B cells in patients with pSS [4,5].
Conclusion
We have shown a new capacity of SGECs to express and
secrete BAFF after stimulation by IFN. This peculiar property
of epithelial cells is enhanced in patients with pSS and con-
firms the importance of resident cells of target organs in induc-
ing or perpetuating autoimmunity and the pivotal role of
epithelial cells in the pathophysiological aspects of pSS. To a
larger extent, our results suggest a complex modulation of
BAFF expression depending on the pattern of cytokines
involved in each autoimmune disease and on the cytokine sen-
sitivity of resident cell types present in target organs. In pSS,
BAFF could be a mediator between innate and adaptative
immunity, leading to the stimulation of autoreactive B cells.
Last, as suggested [58], our results give some arguments in
favor of a therapeutic effect of an anti-BAFF approach in pSS.
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